About

Bobby Gaspar is a Venture Partner with F-Prime Capital based in London. Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. He is one of the principal scientific founders and current chief executive officer of Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) gene therapy technology—including some of the first studies in patients with severe primary immune deficiencies—bringing it from some of the first studies in patients into late-stage clinical trials. His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with metachromatic leukodystrophy (MLD) and other severe genetic conditions through targeted disease education, early diagnosis and comprehensive newborn screening.

Bobby was named to the inaugural TIME100 Health list in 2024, recognizing him as one of the world’s most influential individuals impacting human health. In addition to his role at Orchard, Bobby also serves as the chair of the board of directors at Eligo Biosciences, a privately-held biotech company expanding the scope of genetic medicines through gene-editing of the microbiome. He is also a venture partner at F-Prime, a global venture creation and investment firm with $4.5 billion under management.

Bobby is an honorary professor of pediatrics and immunology at the University College London (UCL) Great Ormond Street Institute of Child Health and has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Great Ormond Street Institute of Child Health.